Apollo in Talks to Acquire Johnson & Johnson's Orthopedics Unit for Nearly $20 Billion, Report Says

Private equity firm Apollo Global Management is in discussions to acquire the orthopedics business of healthcare conglomerate Johnson & Johnson, according to a media report. The potential deal could value the unit at close to $20 billion.

The Potential Transaction

Bloomberg News reported on Friday that the two companies were in talks, citing sources familiar with the matter. The discussions are preliminary and there is no guarantee that an agreement will be reached. Reuters stated it could not independently verify the report.

If completed, the acquisition would be a significant move for Apollo, adding a major player in the medical device market to its portfolio. The orthopedics division manufactures products for joint replacement, trauma, and spine procedures.

Strategic Context

Ad

A potential sale would align with Johnson & Johnson's recent strategy of streamlining its operations to focus on its higher-growth pharmaceutical and medical technology segments. This follows the company's successful spinoff of its consumer health division, now known as Kenvue.

For investors, a divestiture of the orthopedics unit could unlock value and allow J&J to concentrate capital on more innovative areas. For Apollo, the acquisition of a business with stable, long-term demand driven by an aging population would fit a typical private equity investment thesis.

Market Implications

The orthopedics market is a mature and competitive space, and a change in ownership could reshape the competitive landscape. Large-scale divestitures by conglomerates often signal a strategic pivot, and market participants will be watching for official statements from either company regarding the reported talks.